Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – What’s Next?

Structure Therapeutics Inc. (NASDAQ:GPCR)’s stock price gapped up prior to trading on Wednesday . The stock had previously closed at $20.53, but opened at $22.26. Structure Therapeutics shares last traded at $22.29, with a volume of 147,225 shares changing hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Stifel Nicolaus initiated coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, William Blair began coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They issued an “outperform” rating on the stock. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Down 4.8 %

The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -27.57 and a beta of -2.35. The company’s 50 day moving average is $25.45 and its 200 day moving average is $32.57.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. On average, analysts expect that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Spire Wealth Management acquired a new position in Structure Therapeutics during the fourth quarter worth about $243,000. JPMorgan Chase & Co. increased its position in Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock worth $1,489,000 after purchasing an additional 25,500 shares in the last quarter. Vestal Point Capital LP lifted its stake in Structure Therapeutics by 105.4% in the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock valued at $50,474,000 after purchasing an additional 590,000 shares during the last quarter. Barclays PLC boosted its position in Structure Therapeutics by 64.5% in the third quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after buying an additional 31,815 shares in the last quarter. Finally, Pier Capital LLC grew its stake in shares of Structure Therapeutics by 32.7% during the third quarter. Pier Capital LLC now owns 134,291 shares of the company’s stock worth $5,894,000 after buying an additional 33,087 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.